Remedy Pharmaceuticals Secures Key U.S. Patent Allowance for CIRARA® in Treating Large Hemispheric Infarction, Including Wake-Up Strokes

PRESS RELEASE

NEW YORK, March 18, 2025 – Remedy Pharmaceuticals, a leader in stroke drug development, today announced that the U.S. Patent and Trademark Office (USPTO) has allowed two additional patents covering its large hemispheric infarction (LHI) drug, CIRARA (IV glyburide).  

The allowances include a claim covering the use of CIRARA’s active pharmaceutical ingredient, glyburide, or any other SUR1-TRPM4 inhibitor, to treat patients with a LHI and a lesion volume of 50-125 mL who undergo endovascular therapy (EVT), a minimally invasive mechanical procedure used to remove blood clots from large arteries in the brain. EVT has recently become the standard of care in treating LHI. Clinical evidence has shown that CIRARA is highly effective in combination with EVT in this lesion range, with an Odds Ratio of 8.19 (p=0.01) favoring CIRARA treatment over placebo. 

“This claim covers the treatment of patients expected to be included in the primary analysis group of any Phase 3 study designed to gain regulatory approval,” says Sven Jacobson, CEO of Remedy Pharmaceuticals, “and the allowance aligns with current clinical standards for treating LHI patients.”

The allowances also relate to the use of CIRARA’s active pharmaceutical ingredient, glyburide, or any other SUR1-TRPM4 inhibitor, to treat wake-up stroke patients undergoing EVT.  Wake-up strokes, which account for 20-25% of all strokes, occur during sleep, such that patients awaken with symptoms that were absent at bedtime. In the CHARM study, patients receiving CIRARA in this subgroup were nearly six times more likely to achieve a favorable outcome compared to those on placebo (Odds Ratio: 5.7, p=0.01).

Additionally, the allowances cover the use of Remedy’s proprietary formulation of glyburide (CIRARA) to treat patients with LHI who experience a wake-up stroke and present with a NIH Stroke Scale Score (NIHSS) ≤ 20, irrespective of whether the patient undergoes EVT. The NIHSS is a widely used measure of stroke severity, with a score of 20 representing the boundary of “moderate-to-severe” strokes. 

“These latest allowances strengthen our already extensive patent portfolio,” notes Jacobson, “and further validate CIRARA’s potential to transform LHI stroke care for patients who currently have limited options.”

Both patents provide coverage through June 2044, with the possibility of extending one to June 2049.

About Large Hemispheric Infarction

A large hemispheric infarction is a particularly severe type of ischemic stroke that affects a substantial portion of the brain. Treatment for LHI typically involves rapid revascularization strategies to restore blood flow, such as mechanical thrombectomy or intravenous thrombolysis. However, the large scale of the infarction and the resultant severe edema leads to poorer outcomes compared to smaller strokes, with many patients suffering long-term disability or death.

About Remedy Pharmaceuticals:

New York-based Remedy Pharmaceuticals, Inc. is a privately held, clinical-stage pharmaceutical company focused on developing and bringing lifesaving treatments to people affected by acute central nervous system (CNS) injuries. 

Contact:

Sven Jacobson

CEO

Remedy Pharmaceuticals

212.586.2226

sven@remedypharmaceuticals.com

www.remedypharmaceuticals.com

Scroll to Top

From Setbacks to Breakthroughs: Remedy Pharmaceuticals' Unwavering Quest to Transform Stroke Treatment

Drug development is a complex and challenging endeavor, marked by years of struggle, hard work, disappointments, and occasional triumphs. The story of Remedy Pharmaceuticals and our innovative stroke treatment, CIRARA, is no exception.

Each year, approximately 700,000 Americans suffer from ischemic strokes (some 14 million worldwide), with a particularly devastating subset classified as Large Hemispheric Infarctions (LHI). These strokes, which account for 10-15% of all ischemic strokes, are characterized by large infarcts (typically more than 70mL — approximately half a tennis ball) which frequently leads to massive brain edema, brain tissue shifts, herniation, and death.

Despite advancements like the clot-buster drug, rtPA, and mechanical clot removal through endovascular therapy (EVT), functional outcomes for LHI remain poor, and mortality rates high.

Remedy’s drug, CIRARA, targets a critical regulator of cerebral edema, the SUR1-TRPM4 channel. During an ischemic stroke, SUR1-TRPM4 channels become upregulated and open due to ATP depletion, leading to sodium influx, cell swelling, and disruption of the blood-brain barrier. By inhibiting this channel, CIRARA prevents the formation of this damaging and often life-threatening edema, potentially offering a new lease on life for patients suffering from LHI.

The journey of CIRARA began with the discovery of the SUR1-TRPM4 channel by Dr. J. Marc Simard at the University of Maryland School of Medicine. The founders of Remedy Pharmaceuticals licensed the technology to develop CIRARA from a scientific finding into a life-saving therapy.

Early trials (a Phase 2a pilot study and the Phase 2b study known as GAMES-RP) provided promising signals, demonstrating reduced mortality and improved functional outcomes in LHI patients.

In 2017, while Remedy was in the midst of planning a Phase 3 study, Biogen acquired CIRARA, and in late 2018 launched the Phase 3 CHARM study. Despite passing an interim analysis designed to determine whether proceeding was futile, Biogen’s strategic shift away from acute neurology led to the premature termination of the study in 2023.

Data from the CHARM study was transferred to Remedy Pharmaceuticals in 2024, at which point the company performed pre-specified and post hoc analyses. Pre-specified analyses of the CHARM study data revealed compelling results: CIRARA demonstrated statistically significant efficacy in patients with an NIH Stroke Scale (NIHSS) ≤20 (n=274) with an Odds Ratio of 1.8 (p=0.01), and LHI patients who also underwent EVT appeared to particularly benefit, with an Odds Ratio of 1.76 in favor of CIRARA, although this was not statistically significant.

Further analyses showed that in patients with ischemic lesion volumes < 125 mL, the Odds Ratio in favor of CIRARA was 2.15 (p=0.04). In patients with lesion volumes < 125 mL undergoing EVT, the odds ratio was 7.13 (p=0.01) in favor of CIRARA underscoring its substantial impact on functional outcomes which was accompanied by a dramatic 81% reduction in mortality without increasing severe disability.

Further post hoc analyses have now been performed and show that the Odds Ratio for achieving an mRS score of 0-3 (moderate disability or better) in patients with a lesion volume < 125 mL was 4.1 in favor of CIRARA (p<0.01). An mRS of 0-3 reflects moderate disability or less, which includes the ability to ambulate independently, a highly desirable outcome in LHI.

In the EVT population with a lesion volume <125 mL, the OR for achieving an mRS score of 0-3 was 18.5 in favor of CIRARA (p=0.03), indicating an even more dramatic improvement in functional outcomes, particularly in the ability to ambulate independently.

LHI is characterized by the development of life-threatening cerebral edema which causes the brain to shift past its center line, a phenomenon known as midline shift (MLS). MLS is associated with neurological deterioration and mortality, and MLS > 5 mm is considered a critical tipping point, indicating severe swelling and a higher risk of poor outcomes. In patients with lesion volumes < 125 mL who underwent EVT, CIRARA reduced MLS at 72 hours by 41% (3.4mm vs 5.8mm, p=0.02).

These findings were consistent with earlier results from the GAMES-RP study, reinforcing that, following a confirmatory study, CIRARA could become a game-changer in LHI treatment.

Thus, despite the setbacks, the story is far from over. With CIRARA squarely back in Remedy’s hands, we are ready to write the remaining chapters.

Looking ahead, Remedy is planning a pivotal Phase 3 trial that will confirm CIRARA’s effect in LHI patients with lesion volumes below 125 mL who undergo EVT. This carefully designed study seeks to build on the robust data already gathered and propel CIRARA towards regulatory approvals.

The estimated potential peak sales figure for CIRARA is approximately $2 billion. Between the patent portfolio developed by Remedy (both before the Biogen deal and after the asset’s return) and a new formulation patent developed by Biogen that is now owned by Remedy, the company has built a thicket of patent claims from multiple patent families, providing exclusivity by way of treatment method, dosing regimen, and formulation patents with expiry dates into the mid-late 2040s.

In the world of medicine, where each day can mean the difference between life and death, the stakes are incredibly high. So too is Remedy’s commitment. We have faced numerous obstacles and have emerged with a clear vision and an unwavering determination to see CIRARA through to its full potential. We are not just developing a drug for LHI; we are igniting hope of better days ahead for stroke patients and their families.

For now, we leave you with the words of Dr. Gregory W. Albers, Director of the Stanford Stroke Center, “After three decades of searching for an effective neuroprotective treatment, I believe we are finally on the verge of a breakthrough. CIRARA has more promising efficacy data than any of the previously tested agents.”